The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IWWM-12 2024 | IgM de-myelinating neuropathy as a complication of MGUS and WM
Shirley D’Sa, MD, FRCP, FRCPath, University College London, London, United Kingdom, discusses IgM de-myelinating neuropathy as a complication of monoclonal gammopathy of undetermined significance (MGUS) and Waldenström’s macroglobulinemia (WM). She notes that rituximab is commonly used to treat this complication, with alternative options like BTK inhibitors available if rituximab proves ineffective. This interview took place at the 12th International Workshop on Waldenström’s Macroglobulinemia (IWWM-12) in Prague, Czech Republic.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
